Advice
In the absence of a submission from the holder of the marketing authorisation:
drospirenone (Slynd®) is not recommended for use within NHSScotland.
Indication under review: contraception.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result, we cannot recommend its use within NHSScotland.
The holder of the marketing authorisation has indicated that they plan to make a submission to SMC in the future.
Download detailed advice228KB (PDF)
Medicine details
- Medicine name:
- drospirenone (Slynd)
- SMC ID:
- SMC2725
- Indication:
Contraception
- Pharmaceutical company
- Exeltis UK Ltd
- BNF chapter
- Obstetrics, gynaecology, and urinary-tract disorders
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 07 October 2024